Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.

Molecular biology reports - 13 Jan 2024

Sito Hilary, Tan Shing Cheng

Abstract excerpt

Platinum-based chemotherapy (PBC) is a widely used treatment for various solid tumors, including non-small cell lung cancer (NSCLC). However, its efficacy is often compromised by the emergence of drug resistance in patients. There is growing evidence that genetic variations may influence the susceptibility of NSCLC patients to develop resistance to PBC. Here, we provide a comprehensive overview of the mechanisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Pharmacogenetics

Share to Platinum

Share to Polymorphism, Genetic

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 38217759
DOI: 10.1007/s11033-023-08915-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.PMID 38217759Read ↗

Pharmacogenomics of platinum-based chemotherapy in NSCLCSemantic proximity Read ↗

Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.Semantic proximity Read ↗

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Semantic proximity Read ↗

Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta-Analysis.Semantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patientsSemantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.Semantic proximity Read ↗

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Semantic proximity Read ↗

[Single nucleotide polymorphisms in lung cancer patients and cisplatin treatment].Semantic proximity Read ↗

Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy.Semantic proximity Read ↗

ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients.Semantic proximity Read ↗

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based ChemotherapySemantic proximity Read ↗

Lung cancer, platinum analog-based frontline treatment and pharmacogenetic limitations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.